Mantle cell lymphoma: a Turkish Multi-Center Study

Purpose: Mantle Cell Lymphoma (MCL) is a B-cell neoplasm with CCND1 [t(11;14)(q13;q32), cyclin D1] translocation. The guidelines recommend various treatment options based on age, performance status and comorbidities. Our purpose was to analyze the clinical features and evaluate prognostic factors for survival of 78 MCL patients. Methods: We retrospectively analyzed all MCL patients in two reference Hematology Departments between January 2001 and September 2018. Results: The patient median age was 62 years (34-86) and 78.2% of them were male. The treatment regimens were R-CHOP in 42.3%, R-Bendamustine in 26.9%, HyperCVAD in 9% and R-CHOP/R-DHAP alternating in 7.7%. Only 13 patients underwent autologous stem cell transplantation. Median overall survival (OS) was 77.8 months (53.8-101.8) and median disease-free survival (DFS) was 20.6 months (14.2-26.9), all patients included. Univariate analysis showed that MCL International Prognostic Index and neutrophil count effected OS in all groups (p=0.047 and p=0.001). Multivariate analysis showed that the neutrophil count at diagnosis was independent prognostic risk factor (HR=0.209, 95% confidence interval 0.0690.629, p=0.005) for OS. The median OS was 77.8 months in absolute neutrophil count (ANC) less than 7.5x10(3)/mu L and 14.8 months in ANC more than 7.5x10(3)/mu L (p=0.001). Conclusions: Median OS is somewhat prolonged in the last years with new treatment approaches but MCL is still an incurable disease. The first choice of treatment in MCL patients was R-CHOP. Higher neutrophil count at the time of diagnosis has a detrimental effect on OS.